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External Validation of the UKPDS
Risk Engine in Incident Type 2
Diabetes: A Need for New Type 2
Diabetes–Speciﬁc Risk Equations
OBJECTIVE
To evaluate the performance of the UK Prospective Diabetes Study Risk Engine
(UKPDS-RE) for predicting the 10-year risk of cardiovascular disease end
points in an independent cohort of U.K. patients newly diagnosed with type 2
diabetes.
RESEARCH DESIGN AND METHODS
This was a retrospective cohort study using routine health care data collected
between April 1998 and October 2011 from ∼350 U.K. primary care practices
contributing to the Clinical Practice Research Datalink (CPRD). Participants com-
prised 79,966 patients aged between 35 and 85 years (388,269 person-years) with
4,984 cardiovascular events. Four outcomes were evaluated: ﬁrst diagnosis of
coronary heart disease (CHD), stroke, fatal CHD, and fatal stroke.
RESULTS
Accounting for censoring, the observed versus predicted 10-year event rates were
as follows: CHD 6.1 vs. 16.5%, fatal CHD 1.9 vs. 10.1%, stroke 7.0 vs. 10.1%, and
fatal stroke 1.7 vs. 1.6%, respectively. The UKPDS-RE showed moderate discrim-
ination for all four outcomes, with the concordance index values ranging from
0.65 to 0.78.
CONCLUSIONS
The UKPDS stroke equations showed calibration ranging from poor to moderate;
however, the CHD equations showed poor calibration and considerably overes-
timated CHD risk. There is a need for revised risk equations in type 2 diabetes.
Diabetes Care 2014;37:537–545 | DOI: 10.2337/dc13-1159
National policies for the management of both cardiovascular disease (CVD) and
type 2 diabetes advocate the calculation of CVD risk in order to identify high-risk
patients for targeted interventions (1–5). Several multivariable risk prediction
models (or risk scores) have been developed for the general, nondiabetic population
that also account for diabetes, but only a few are speciﬁc to type 2 diabetes (6). Only
two of these have been developed in patients with newly diagnosed type 2 diabetes,
and they both use data from the UK Prospective Diabetes Study (UKPDS) (7). These
twomodels, one for coronary heart disease (CHD) and the other for stroke, combine
to form the UKPDS Risk Engine (UKPDS-RE) (8,9).
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International and national clinical
guidelines recommend using the
UKPDS-RE for predicting cardiovascular
risk (5,10–12). Not only is the UKPDS-RE
advocated for communicating
cardiovascular risk to diabetic patients
(13), it has been relied upon for public
health decisions (14–17). Evidence that
these equations are inadequate could
bring into question the evidence base
underpinning many clinical decisions
and public policies about the
management of type 2 diabetes. Two
systematic reviews of external
validations of type 2 diabetes
cardiovascular risk prediction models
(6,18) reported poor calibration of the
UKPDS-RE CHD equations in 10 separate
studies (19–28) and differing ﬁndings for
the stroke equations in two separate
studies (23,25). The largest of these
studies from the U.K. used only a small
sample (n = 798) from a single locality
(21). The largest international study
had a larger but still relatively small
sample size (n = 7,502) using data
collated from 20 countries (23).
The purpose of this study was to carry
out an external evaluation of the
performance of the UKDPS-RE on a
large, relatively contemporary dataset
of U.K.-resident patients newly
diagnosed with type 2 diabetes.
RESEARCH DESIGN AND METHODS
This study was performed using data
from the Clinical Practice Research
Datalink (CPRD) and linked data from
the Ofﬁce for National Statistics (ONS)
and Hospital Episode Statistics (HES).
Ethical approval for the study was
granted by the CPRD Independent
Scientiﬁc Advisory Committee on 6
September 2012, protocol number
12_084R.
The CPRD observational dataset consists
of longitudinal, anonymous records
from nearly 700 primary care practices
and .11 million patients throughout
the U.K. (based on the January 2012
release) (29). The computerized data,
recorded in the course of routine
health care by general practitioners
(GPs) and associated staff, include
demographic and lifestyle information,
medical history, clinical investigations,
drug prescriptions, and hospital
referrals. Diagnoses in CPRD are
recorded using the Read code
classiﬁcation and have been validated
in a number of studies, showing a high
positive predictive value (30).
Additionally, 357 of the English practices
contributing to the dataset,
representing ;45% of CPRD patients,
participate in a linkage scheme by which
registered patients are anonymously
linked, through a trusted third party, to
other independent datasets (31). These
include hospital admission data,
collated nationally for England as the
HES (32), and mortality data, collated by
the ONS (33). HES provides details of all
National Health Service (NHS) inpatient
admissions in England since 1997,
including primary and contributory
causes coded using the ICD-10
classiﬁcation. ONS provides details of all
deaths in England, with immediate and
antecedent causes coded using the ICD-
9 and ICD-10 classiﬁcations.
For this study, a single cohort of patients
with incident type 2 diabetes, registered
with practices between 1998 and 2011,
was identiﬁed from the CPRD dataset as
described below. In order to improve
ascertainment of cardiovascular events,
only patients whose records linked to
the HES and ONS mortality datasets
were included, with the former
providing details of diagnoses and
procedures related to inpatient
episodes, and the latter providing both
the date and cause(s) of death. The HES
data also provided the ethnicity
information required for the study.
Patients aged between 35 and 84 years
at diagnosis were included in the study.
As the original UKPDS-RE was based on a
cohort aged ,65 years, a sensitivity
analysis was performed. Patients were
excluded if they had ongoing or recent
CVD (as deﬁned by the UKPDS study
criteria), implausible or improbable
dates, or missing or indeterminate sex
or smoking status. Patients that were
HES-eligible but had no records in the
linked HES data were excluded (n =
1,727). Patients whose ethnicity was not
recorded (n = 29,199) were presumed
Caucasian and combined with the
Caucasian group.
Selection of Type 2 Diabetic Patients
Patients were considered for selection if
they had a clinical (Read or ICD-10) code
indicative of diabetes in their CPRD or
linked HES records. As not all clinical
codes for diabetes distinguish between
type 1 and type 2 diabetes, and some
patient histories may have erroneously
contained both type 1 and type 2
diabetes codes, these patients were
categorized as having type 2 diabetes if
they met one or more of the following
criteria: 1) clinical codes exclusively
indicative of type 2 diabetes; 2) at least
one clinical code indicative of type 2
diabetes (regardless of others indicative
of type 1 or nonspeciﬁc diabetes) and at
least one prescription for an oral
hypoglycemic agent (OHA); 3)
prescription of two or more classes of
OHA; and 4) diagnoses of both type 1
and type 2 diabetes and an age of
diagnosis older than 35 years. Any
patient with evidence of diabetes
secondary to other causes was
excluded.
The date of diabetes incidence was
deﬁned as the date of either ﬁrst
diagnosis or ﬁrst prescription of a
diabetes medication, whichever was
earlier. A “wash-in” period of 365 days
was applied to exclude nonincident type
2 diabetes cases.
Outcome Measures
The primary outcomes comprised the
four cardiovascular events evaluated by
the UKPDS-RE: CHD, fatal CHD, stroke,
and fatal stroke. To aid comparison, the
deﬁnitions of the outcomes in the CPRD
cohort were the same as the deﬁnitions
from the UKPDS (7–9). CHD was deﬁned
as the occurrence of fatal or nonfatal
myocardial infarction (MI) or sudden
death (7). In patients with multiple CHD
events, only the ﬁrst event was
considered. No distinction was made
between ischemic and hemorrhagic
strokes. In patients with multiple
strokes, only the ﬁrst stroke was
considered. Deaths from causes other
than the deﬁned outcomes of interest
were treated as censored. Occurrence
of clinical events of interest in CPRD was
observed from GP-recorded diagnoses,
diagnoses recorded during a hospital
admission, or cause of death.
Input Variables
Values for the input variables required
for the UKPDS-RE were taken from CPRD
observations around the time of
diabetes incidence. Table 1 shows the
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baseline characteristics at the time of
incident diabetes. Baseline smoking
status was the value recorded closest to
diabetes incidence, preferring values
recorded prior to diabetes incidence; for
systolic blood pressure (SBP), glycated
hemoglobin A1c (HbA1c), total
cholesterol, and HDL cholesterol, the
baseline value was the average of
biochemical readings recorded in the
ﬁrst 2 years. The numbers of readings
used in deriving these 2-year averages
were also recorded for use as input
parameters (regression dilution) in the
UKPDS-RE (9). Atrial ﬁbrillation was
deemed present at baseline if a prior
diagnosis or record of a CHADS2 test
existed (CHADS2: congestive heart
failure, hypertension, age $75 years,
diabetes, prior stroke or transient
ischemic attack).
Multiple imputation was used to replace
missing values for SBP, HbA1c, total
cholesterol, HDL cholesterol, and the
number of biochemical readings used in
their 2-year averages. Multiple
imputation is a technique that offers
substantial improvements over value
replacement approaches based on
complete cases or cases matched for
age and sex (34). It involves creating
multiple copies of the data and imputing
the missing values with plausible values
randomly selected from their predicted
distribution. Here, we used the
multivariate imputation by chained
equations (MICE) library in the R (35)
statistical programming language to
generate ﬁve imputed datasets. Rubin’s
rules were then used to combine the
results from analyses on each of the
imputed values, producing estimates
and conﬁdence intervals that
incorporate the uncertainty of imputed
values.
Statistical Analysis
For each of the four outcomes, the 10-
year estimated risk was calculated for
every patient in the CPRD cohort using
the UKPDS-RE (8,9). Observed 10-year
risks were generated using the Kaplan-
Meier method, by decile of predicted
risk and by 5-year age-group. The
predictive performance of the UKPDS-
RE on the cohort was assessed by
examining measures of calibration and
discrimination.
Calibration refers here to how closely
the predicted 10-year cardiovascular
risk agreed with the observed 10-year
cardiovascular risk. This was assessed
for each decile of predicted risk,
ensuring 10 equally sized groups, and
for each 5-year age-group by calculating
the ratio of predicted to observed
cardiovascular risk separately for males
and females. Plotting observed
proportions versus predicted
probabilities, where a 458 line denoted
perfect discrimination, enabled the
calibration of the risk score predictions
to be visually assessed.
Discrimination is the ability of the risk
score to differentiate between patients
who did and did not experience an event
during the study period. This measure
was quantiﬁed by calculating a
concordance index (C index), in which a
value of 0.5 represents random chance
and 1 represents perfect discrimination.
All statistical analyses were carried out
in R (v2.15.2) (35).
RESULTS
We identiﬁed 79,966 eligible cases, who
contributed 383,025, 388,269, 381,833,
and 388,004 person-years of observed
follow-up for CHD, fatal CHD, stroke,
and fatal stroke, respectively. The
incidence rates for cardiovascular
events in the CPRD cohort were 59.2
(95% CI 56.8–61.6), 16.8 (15.5–18.1),
71.2 (68.5–73.2), and 15.2 (14.0–16.5)
per 10,000 person-years for CHD, fatal
CHD, stroke, and fatal stroke,
respectively. The median durations of
follow-up were 4.2 years (IQR 2.0–7.2),
4.3 (2.1–7.3), 4.2 (2.0–7.2), and 4.3 (2.1–
7.3), respectively. The proportions of
cases followed for 10 years or more
were 8.5, 8.8, 8.4, and 8.8%,
respectively. Table 1 details the
characteristics of these patients at or in
the ﬁrst 2 years from diabetes diagnosis
(baseline). People recruited to the
UKPDS were a very unusual group of
people with type 2 diabetes, and this is
reﬂected in the baseline characteristics.
For instance, the mean age at baseline
for females in the UKPDS was 53 vs.
63 years in general clinical practice
(Table 1).
Missing Data
Complete data on age, ethnicity,
smoking status, atrial ﬁbrillation status,
SBP, HbA1c, total cholesterol, and HDL
cholesterol were available for 70% of
females (n = 43,741) and 74% of males
(n = 54,710). Most patients (n = 120,572;
88.3%) had missing data on no more
than two risk factors (Supplementary
Table 1). For speciﬁc covariates, the
proportion of missing data were as
Table 1—Characteristics of patients in the CPRD cohort and UKPDS
Characteristic
Females Males
CPRD UKPDS CPRD UKPDS
n 36,746 1,879 43,220 2,643
Age (years), mean (SD) 62.6 (12.3) 52.7 (8.7) 60.3 (11.6) 51.5 (8.8)
Ethnicity (%)
Caucasian/not recorded 35,452 (96.5) 1,603 (85.0) 42,009 (97.2) 2,151 (81.0)
Afro-Caribbean 404 (1.1) 153 (8.1) 350 (0.8) 201 (7.6)
Asian-Indian 890 (2.4) 141 (7.4) 861 (2.0) 2,91 (11.0)
Smoking status (%)
Nonsmoker 19,684 (54) – 16,207 (37) ―
Former smoker 10,715 (29) ― 18,173 (42) ―
Current smoker 6,347 (17) 474 (25) 8,840 (20) 898 (34)
SBP (mmHg), mean (SD)* 139 (14) 139 (21) 139 (13) 133 (18)
HbA1c (%), mean (SD)* 7.0 (1.2) 6.9 (1.5) 7.1 (1.2) 6.6 (1.4)
Total cholesterol (mmol/L),
mean (SD)* 5.0 (0.9) 5.7 (1.1) 4.7 (0.9) 5.2 (1.0)
HDL cholesterol (mmol/L),
mean (SD)* 1.37 (0.32) 1.18 (0.27) 1.17 (0.27) 1.06 (0.23)
Total/HDL cholesterol ratio,
mean (SD)* 3.85 (1.03) ― 4.16 (1.11) ―
Values are at baseline and are numbers (percentages) unless otherwise stated. *Mean of values
in the ﬁrst 2 years from baseline (HbA1c, SBP, and cholesterol).
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follows: HDL cholesterol (26.2% in
females and 23.6% in males), SBP (4.1%
in females and 3.7% in males), HbA1c
(8.1% in females and 12.0% in males),
and total cholesterol (9.5% in females
and 12.3% in males) (Supplementary
Table 1).
Discrimination and Calibration
A visual illustration of the agreement
between mean observed risk and the
mean predicted risk, grouped by decile
of predicted risk for each of the four
UKPDS-RE outcomes is shown in Fig. 1.
Presenting these data in an alternative
way, Fig. 2 shows the agreement
between the observed risk and the
predicted risk by 5-year age- and sex-
speciﬁc groups for each of the
outcomes. Both the CHD models were
clearly miscalibrated, notably for males
(overestimating event rates by 174 and
466%, compared with 160 and 398% in
females, for CHD and fatal CHD,
respectively) and most notably for fatal
CHD (overestimating event rates by
440%). There was a clear and consistent
overprediction of risk across all deciles
of predicted risk, and across all age- and
sex-speciﬁc groups. The disagreement
between observed proportions and
predicted risks increased in subsequent
deciles of risk and in the older age-
groups (Figs. 1 and 2). The stroke model
overestimated event rates by 29 and
58% in females and males, respectively,
and the fatal stroke model
underestimated event rates by 20% in
males and overestimated these rates by
11% in females. The stroke models
showed modest agreement between
observed and predicted risk grouped by
decile of risk, with the exception of the
ﬁnal, 10th decile for the stroke model in
both males and females (Figs. 1 and 2).
Both the stroke and the fatal stroke
models showed modest agreement
across all age-groups, with some
divergence toward the latter age ranges
(70–85 years), most noticeably for
males in the stroke model. The fatal
stroke model slightly underpredicted
risk for the latter age-groups, whereas
the stroke model tended to overpredict
risk for these latter age-groups.
Table 2 summarizes the performance of
the four UKPDS-RE models in predicting
the 10-year risk in type 2 diabetic
patients who were initially free of CVD.
The UKPDS-RE overestimated the risk of
CHD, fatal CHD, and stroke by 169, 440,
and 44%, respectively, and
Figure 1—Observed vs. predicted 10-year risk by sex and outcome.
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underestimated the risk of fatal stroke
by 5%. According to the C index, all
models were found to have acceptable
model discrimination, with the
exception of the CHD model in males (C
index = 0.65), which was found to have
modest discrimination. The C-index
values for females and males,
respectively, were as follows: for the
CHD model, 0.71 and 0.65; for the fatal
CHD models, 0.78 and 0.74; for the
stroke models, 0.73 and 0.71; and for
the fatal stroke models, 0.77 and 0.78.
All the models showed better
discrimination in females, with the
exception of fatal stroke, and better
discrimination (and variability in
estimates) in fatal outcomes in both
females and males. Of all the models
evaluated, fatal stroke demonstrated
the best prognostic separation, with
discrimination results ranging from
acceptable to good (0.77 and 0.78 in
females and males, respectively),
whereas CHD exhibited the worst
prognostic separation, most noticeably
in males, with discrimination results
ranging from modest to acceptable
(0.71 and 0.65).
CONCLUSIONS
This validation study showed that the
risk equations that constituted the
UKPDS-RE were poorly calibrated and
signiﬁcantly overestimated CHD risk.
The stroke equations showed
calibration ranging from poor to
moderate. All the UKPDS-RE equations
showed moderate discrimination, with
slightly better discrimination for fatal
events. This ﬁnding was concordant
with several other much smaller,
external validation studies (,8,000
subjects) that also showed poor
calibration and overestimation of CHD
risk by the UKPDS-RE (19–28). To date,
this is the largest study, with ;80,000
patients, and the most comprehensive
external validation of cardiovascular risk
prediction in a diverse and more
contemporary population with type 2
diabetes.
The relatively poor performance of the
UKPDS-RE may be explained, at least in
part, by the differences in the baseline
proﬁles of the UKPDS and CPRD
populations. These plausibly include the
epidemiological setting, changesin life
expectancy, changes in smoking habits,
the presence or absence of
Figure 2—Observed and predicted 10-year risks by age-group, sex, and outcome (solid lines represent observed proportions and dashed predicted
risk).
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comorbidities, temporal changes in
diabetes management, and changes in
the general quality of care. Other
plausible explanations include the
possible harm of overly aggressive
treatment with sulfonylureas and insulin
in the early stages of the disease (36).
The CPRD cohort used in this study was
drawn from the U.K. general practice
and identiﬁed 79,966 patients aged 35–
85 years newly diagnosed with type 2
diabetes and registered between 1998
and 2011. The data used to derive the
UKPDS-RE risk equations originated
from a randomized trial of 5,102 U.K.
patients aged 25–65 years newly
diagnosed with type 2 diabetes and
recruited between 1977 and 1991
(followed up until 1997) (7). The CPRD
cohort comprised patients aged 35–85
years for two reasons: patients under 35
years of age were excluded to reduce
misclassiﬁcation of type 1 diabetes, and
patients 66–85 years of age were
included to reﬂect the fact that National
Institute for Health and Care
Excellence (NICE) guidelines
recommend using the UKPDS-RE for all
ages (13). Of the 79,966 patients in the
CPRD cohort, 31,179 (39%) were outside
the 25–65 age range, and a sensitivity
analysis suggested that the inclusion of
older subjects aged 65–85 years did not
signiﬁcantly affect calibration or
discrimination.
A number of the UKPDS trial’s exclusion
criteria, namely, macrovascular
complications, ketonuria, nephropathy,
severe retinopathy, malignant
hypertension, uncorrected
endocrinopathy, and severe concurrent
illness, were not applied to the CPRD
cohort because their presence would
not preclude the use of the UKPDS-RE in
clinical practice (7). It is important to
note that, by the nature of trial selection
criteria, UKPDS recruits weremore likely
to be of lower risk, suggesting that the
UKPDS-RE would be expected to
underestimate risk when applied to the
CPRD cohort. Overall, the UKPDS-RE
overestimated cardiovascular risk in the
CPRD cohort, suggesting that, in spite of
the additional exclusion criteria, the
UKPDS patients were at higher risk.
A potential difference in the rigor of
ascertainment of primary outcomes
between UKPDS and CPRD warrants
consideration. In this study, we
deliberately limited selection to those
designated by CPRD as being of research
quality, with data linked to HES and ONS
mortality data during their entire
follow-up period. These criteria
combine to make case ascertainment
among the highest of any observational
data sources. Even prior to the
introduction of HES-linked data in CPRD,
the predictive value of GP-recorded
diagnoses of acute MI in the General
Practice Research Database (forerunner
to CPRD) exceeded 90% (37).
The secular differences between the
UKPDS sample and the current CPRD
cohort may have played an important
role. The advent of routine diabetes
screening in primary care in the U.K. has
almost certainly led to earlier diagnosis
of type 2 diabetes than was available at
the time of UKPDS recruitment. This is
supported by an absolute 2% fall in
average incident HbA1c among U.K.
patients with newly diagnosed type 2
diabetes between 1991 and 2012 (38),
although the mean HbA1c at speciﬁc
regimen initiation did not change at all
(39). As such, patients in the UKPDS
cohort are likely to have had more
advanced diabetes at the point of
diagnosis, with correspondingly greater
vascular morbidity.
Over the same period, the diagnosis of
MI has evolved from one based solely on
clinical symptoms to one that may
involve increasingly sophisticated
serological and imaging components,
such that the severity of MI on
admission may plausibly have been
reduced. Post-MI care has also
improved over the period, and
consequently death rates subsequent to
MI have fallen. This may partially explain
why the UKPDS-RE overestimated fatal
CHD, but it does not account for the
same discrepancy in nonfatal CHD,
which by this rationale could be
regarded as conservative.
Another explanation for the
disagreement in the observed and
predicted risk estimates may be the
progressive increase in the use of
effective medication for hypertension
and dyslipidemia over the past 20–30
years. Of the CPRD patients at baseline
(i.e., type 2 diabetes incidence), 22.4%
were taking lipid-lowering medication,
49.2% were taking antihypertensive
Table 2—Summary of UKPDS-RE performance in predicting 10-year cardiovascular risk
CHD Fatal CHD Stroke Fatal stroke
Females Males Females Males Females Males Females Males
n 36,746 43,220 36,746 43,220 36,746 43,220 36,746 43,220
Event rates (%)
Observed 6.14 1.88 7.00 1.69
(95% CI) (5.82–6.45) (1.70–2.06) (6.67–7.33) (1.52–1.86)
4.59 7.44 1.54 2.16 7.28 6.77 1.92 1.50
(4.18–5.01) (6.97–7.90) (1.29–1.79) (1.91–2.42) (6.77–7.79) (6.34–7.20) (1.65–2.19) (1.28–1.72)
Predicted 16.51 10.14 10.10 1.60
(95% CI) (16.43–16.59) (10.07–10.20) (10.00–10.20) (1.58–1.62)
11.94 20.39 7.66 12.24 9.38 10.71 1.53 1.67
(11.86–12.02) (20.31–20.48) (7.60–7.73) (12.18–12.30) (9.28–9.47) (10.61–10.81) (1.51–1.54) (1.65–1.68)
Discrimination
C index 0.71 0.65 0.78 0.74 0.73 0.71 0.77 0.78
(95% CI) (0.69–0.73) (0.63–0.66) (0.75–0.81) (0.72–0.77) (0.72–0.75) (0.70–0.72) (0.74–0.80) (0.76–0.81)
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treatment, and 13.7% were taking
some form of antiplatelet therapy at
baseline. By contrast, the UKPDS was
conducted at a time when the number
of patients taking such medications was
much lower. For example, of the UKPDS
patients at baseline, 0.3% used lipid-
lowering therapy, 12% used
antihypertensive therapy, and 1.6%
used more than one aspirin daily.
Furthermore, during the period of
follow-up, ,2% of UKPDS patients took
lipid-lowering therapy at any stage
compared with 75.3% of the CPRD
cohort (40).
Other changes are also apparent. Only
19% of the CPRD patients were current
smokers at baseline, compared with
30% in the UKPDS. The high relative risk
reduction in CHD afforded by statin
therapy (subsequent to UKPDS) could
have had the effect of reducing the
amount of risk that was then potentially
modiﬁable by other interventions such
as new glucose-lowering therapies. The
beneﬁts of statin therapy are believed to
extend beyond their effect on lipid
proﬁles. This is plausible, given that
UKPDS-RE considerably overestimated
the risk of CHD but not that for stroke.
On the other hand, the speciﬁc risk
markers targeted by these drugs, such
as cholesterol, blood pressure, and
glucose control, are still accounted for
within the UKPDS-RE, so the magnitude
of the discrepancy remains difﬁcult to
explain.
The principal difference between the
CHD and stroke models is the presence
of HbA1c as an input parameter in the
former. The poor calibration of CHD in
this study brings into question the role
of glucose control in predicting
macrovascular complications. In
sensitivity analysis, where decile of
observed HbA1c was used as the
subgroup criterion, there was no
gradient in observed risk of CHD,
contrary to widespread expectation
(Fig. 3). If corroborated, this would
have a signiﬁcant impact on current
clinical management guidelines for type
2 diabetes. Our ﬁndings might also
suggest that, in contemporary practice,
the “beneﬁt” of glucose control (i.e.,
reduction in CHD risk) is being
overstated and consequently is having
an undue inﬂuence on the diagnosis and
treatment of type 2 diabetes.
The overestimation of cardiovascular
risk by the UKDPS-RE may also lead to
unnecessary targeting of patients for
preventative strategies. Accurate
Figure 3—Observed and predicted 10-year risks by HbA1c, sex, and outcome (solid lines represent observed proportions and dashed predicted risk).
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estimation of absolute risk is important
not only for communicating information
on prognosis to patients and
practitioners but also for estimating the
potential risk-beneﬁt balance and cost
effectiveness of therapy. For example,
NICE guidelines for the management of
type 2 diabetes recommend using the
UKPDS-RE and a speciﬁed risk threshold
to identify patients not considered to be
at high cardiovascular risk for lipid-
lowering therapy with statins. Due to
the considerable overestimation of
cardiovascular risk observed in this
study, use of the UKPDS-RE in clinical
practice may potentially lead to harmful
overtreatment of patients with type 2
diabetes.
A major strength of this study was the
size and representativeness of the
cohort. Its limitations are the high levels
of missing data for HbA1c, total
cholesterol, and HDL cholesterol.
Omitting cases with missing data and
performing a complete-case analysis
would have potentially introduced bias
into the study. However, the issue of
missing data was addressed by using
established methods of multiple
imputation. We assumed that people
with missing ethnicity data were white.
This may have biased the ﬁndings to
some small degree, but it is unlikely to
have impacted substantially on our
ﬁndings.
Measurement error in identifying the
CVD outcomes was present in the
analysis, but this study has endeavored
to apply the UKPDS study’s deﬁnitions of
the cardiovascular outcomes as far as
possible in selecting appropriate
medical codes (7). Moreover, we
supplemented the clinical information
recorded in the CPRD with linked but
independent secondary care data from
HES, which included details of primary
and additional diagnoses for inpatient
episodes, and with cause-speciﬁc
mortality data extracted from death
certiﬁcates from the ONS. It is therefore
unlikely that measurement error is a
large source of bias.
Restricting cohort membership to
patients from the subset of English
practices participating in the linkage
scheme between CPRD and HES/ONS
should not have introduced signiﬁcant
bias; patient characteristics have been
found to be similar between linked and
nonlinked practices (30). In order to
provide data on ethnicity, only those
HES-eligible patients with a hospital
contact were included in our cohort.
This excluded only 2% of patients, but
these patients were presumably
healthier than the overall cohort.
Here we have attempted to validate the
UKPDS-RE as a prognostic tool in a
cohort of newly diagnosed subjects. We
did not evaluate its performance with
respect to CVD risk among patients with
established type 2 diabetes. As the CHD
and stroke models each include
duration of diabetes as an input
parameter, exploration of the utility of
UKPDS-RE among prevalent cases of
type 2 diabetes is an important future
objective.
The four UKPDS risk equations
constituting the UKPDS-RE showed a
reasonable ability to identify high-risk
patients (discrimination) but were
generally poor at quantifying the
absolute risk (calibration). The UKPDS-
RE CHD risk equations consistently
overestimated absolute risk, whereas
the UKPDS-RE stroke equations
performed relatively well. However,
when considered as a whole, the
UKPDS-RE was unsuitable for predicting
CVD risk in U.K. subjects with newly
diagnosed type 2 diabetes. Our ﬁndings
suggest that the use of UKPDS-RE in
clinical practice will lead to
overestimation of CVD risk in patients
with newly diagnosed type 2 diabetes.
This in turn is likely to lead to selection
of preventative treatments, for which,
for some patients, the balance of risks
may outweigh the beneﬁts. Considering
the widespread application of these
prediction models in clinical practice,
drug reimbursement, and public health
decision making, we suggest that there
is a need for revised risk equations in
type 2 diabetes.
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Supplementary Table 1. Risk factors used in UKPDS Risk Engine models. 
 
Risk Factor CHD Stroke 
Sex    
Age (at diagnosis, in years)    
Ethnicity   
Smoking status (at diagnosis)    
Atrial fibrillation   
Systolic blood pressure (mmHg)    
HbA1c (%)   
Total: HDL cholesterol ratio    
Duration diabetes (days)    
 
Supplementary Table 2.  Completeness of data. 
 
No. of risk factors not recorded (per 
patient) 
No. (%) of females 
(n=36 746) 
No. (%) of males 
(n= 43 220) 
0 (complete data) 43,741 (70) 54,710 (74) 
2 10,337 (17) 11,784 (16) 
3 2,326 (4) 2,410 (3) 
4 723 (1) 644 (1) 
5 3,670 (6) 2,970 (4) 
6 37 (0) 35 (0) 
7 1,648 (3) 1,598 (2) 
 
   
